COYA.NASDAQCoya Therapeutics, INC
10-K/A: Coya Therapeutics Files Amendment No. 1 to Form 10-K/A for Fiscal Year Ended December 31, 2024
Sentiment:
Form 10-K/A Amendment
Coya Therapeutics files an amendment to its annual report on Form 10-K/A to include previously omitted Part III information and updated certifications.
Summary
- Coya Therapeutics, Inc. filed Amendment No. 1 to its annual report on Form 10-K/A for the fiscal year ended December 31, 2024.
- The amendment includes Part III information (Items 10, 11, 12, 13, and 14) and amends Part IV, Item 15 of the original Form 10-K.
- The company also included new certifications from the principal executive officer and principal financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- The original Form 10-K was filed with the SEC on March 18, 2025.
- The amendment includes information about directors, executive officers, corporate governance, executive compensation, security ownership, related transactions, and accounting fees.
- As of March 14, 2025, the number of outstanding shares of common stock was 16,724,998.
- The aggregate market value of voting and non-voting common equity held by non-affiliates on June 30, 2024, was approximately $85,212,539.
- Weaver and Tidwell, L.L.P. served as the independent registered public accounting firm.
- Audit fees for 2024 were $342,704, and tax fees were $30,450.
- The company has adopted a Code of Business Conduct and Ethics applicable to all officers, directors, and employees.
Sentiment
Score: 7
Explanation: The document is a standard regulatory filing, so the sentiment is neutral to slightly positive. The inclusion of previously omitted information and updated certifications suggests a commitment to transparency and compliance.
Positives
- The company is providing additional transparency by including previously omitted information in the amended filing.
- The inclusion of certifications from the CEO and CFO reinforces accountability.
- The company has a Code of Business Conduct and Ethics in place.
Risks
- The document contains forward-looking statements that are subject to various risks and uncertainties.
- These risks could cause actual results to differ materially from those expressed or implied in the statements.
- Factors that could affect future results are detailed in the 'Risk Factors' section of the original Annual Report on Form 10-K.
Future Outlook
The document contains forward-looking statements regarding the company's plans, beliefs, and expectations, particularly concerning future events and financial performance. These statements are subject to risks and uncertainties, and actual results may differ materially.
Management Comments
- Dr. Swaminathan's expertise in strategic planning and corporate finance, along with his proven track record of success in the life sciences sector, underscores his suitability to serve as a director for our company.
- Our Board believes its administration of its risk oversight function has not affected its leadership structure.
- Our Board believes that having separate positions is the appropriate leadership structure for us at this time and demonstrates our commitment to good corporate governance.
Industry Context
The document does not provide specific details on how this announcement relates to broader industry trends or competitors. However, the filing of an amended 10-K is a standard regulatory procedure for public companies.
Comparison to Industry Standards
- The document does not contain specific comparisons to industry standards.
- Executive compensation arrangements and director independence assessments are typical for publicly traded companies and are subject to regulatory requirements.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Executive Officer | Howard Berman | Arun Swaminathan | October 30, 2024 | Resignation of previous CEO |
| Executive Chairman | N/A | Howard Berman | October 30, 2024 | Appointment of Executive Chairman |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Board Committee Composition | The Board has established an Audit Committee, a Compensation Committee, and a Nominating and Corporate Governance Committee. | N/A | These committees facilitate the management of the business and oversight of key areas. |
| Director Independence | The Board has determined that Dr. Dov Goldstein, Dr. Ann Lee, Dr. Anabella Villalobos, Dieter Weinand and Wilbur L. Ross are independent directors. | N/A | Ensures independent oversight of management. |
Related Party Transactions
- Effective October 30, 2024, Dr. Howard Berman resigned as our Chief Executive Officer.
- On November 1, 2024, we entered into an employment agreement with Dr. Berman pursuant to which he serves as our Executive Chairman.
Stakeholder Impact
- The filing provides stakeholders with additional information about the company's governance and financial matters.
- The company's policies and practices are designed to protect the interests of stakeholders.
Next Steps
- The company will continue to execute its business strategy and monitor risks.
- The Board will continue to oversee risk management and corporate governance.
- The company will file future reports with the SEC as required.
Key Dates
| Date | Description |
|---|---|
| 2020-12-22 | Agreement and Plan of Merger by and among Coya Therapeutics, Inc. and Nicoya Health, Inc. dated December 22, 2020 |
| 2021-01-25 | Board adopted the 2021 Incentive Plan |
| 2021-02-05 | Stockholders approved the 2021 Incentive Plan |
| 2021-03 | Dr. Dov Goldstein, M.D. has been a director since March 2021. |
| 2021-05 | Dr. Anabella Villalobos, Ph.D., has been a director since May 2021. |
| 2021-06 | Dr. Ann Lee, Ph.D. , has been a director since June 2021. |
| 2022-03-14 | Executive Employment Agreement, dated March 14, 2022, by and between Coya Therapeutics, Inc. and David Snyder |
| 2022-03 | David Snyder has served as our Chief Financial Officer and Chief Operating Officer since March 2022. |
| 2022-08-23 | License Agreement by and between Coya Therapeutics, Inc. and ARScience Biotherapeutics, Inc., dated August 23, 2022 |
| 2022-11-17 | Board amended and restated the 2021 Incentive Plan |
| 2022-12-08 | Sponsored Research Agreement, effective as of December 8, 2022, by and between Coya Therapeutics, Inc. and Methodist Hospital Research Institute dba Houston Methodist Research Institute |
| 2023-04 | Dr. Swaminathan joined Coya as Chief Business Officer in April 2023. |
| 2023-07-03 | Executive Employment Agreement, dated July 3, 2023, as amended and restated (the Grossman Employment Agreement), Dr. Grossman serves as our Chief Medical Officer |
| 2023-07 | Fred Grossman, D.O., FAPA has been our President and Chief Medical Officer since July 2023. |
| 2023-12-05 | Development and License Agreement by and among Coya Therapeutics, Inc., Dr. Reddys Laboratories SA, and Dr. Reddys Laboratories Ltd., dated December 5, 2023 |
| 2024-01-01 | Board members shall automatically be granted stock options to purchase 10,000 shares of our common stock on January 1 of each year |
| 2024-05-08 | Stockholders approved an amendment to increase the number of shares authorized for issuance under the 2021 Incentive Plan to 2,571,070 shares on May 8, 2024. |
| 2024-05-17 | Securities Purchase Agreement dated May 17, 2024, by and between Coya Therapeutics, Inc. and the Alzheimers Drug Discovery Foundation |
| 2024-06-04 | First Amendment to DRL Development Agreement, dated June 4, 2024, by and between Coya Therapeutics, Inc. and Dr. Reddys Laboratories SA |
| 2024-06-08 | First Amendment to the Sponsored Research Agreement, effective as of June 8, 2024, by and between Coya Therapeutics, Inc. and Methodist Hospital Research Institute dba Houston Methodist Research Institute |
| 2024-06-30 | The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant, based on the closing price of the shares of common stock on the Nasdaq Capital Market on June 30, 2024, was approximately $85,212,539. |
| 2024-08 | He became a member of the Board of Directors in August 2024 |
| 2024-10-09 | Second Amendment to the Sponsored Research Agreement, effective as of October 9, 2024, by and between Coya Therapeutics, Inc. and Methodist Hospital Research Institute dba Houston Methodist Research Institute |
| 2024-10-22 | Form of Securities Purchase Agreement, by and among the Company and the Purchasers (incorporated by reference to Exhibit 10.1 of the Companys Current Report on Form 8-K filed with the SEC on October 22, 2024). |
| 2024-10-30 | Dr. Berman resigned as our Chief Executive Officer and was appointed our Executive Chairman pursuant to an employment agreement (the Berman Employment Agreement) on October 30, 2024 |
| 2024-10-30 | Dr. Swaminathan serves as our Chief Executive Officer pursuant to an employment agreement (the Swaminathan Employment Agreement) which provides for Dr. Swaminathan to serve as Chief Executive Officer on October 30, 2024 |
| 2024-11-01 | Dr. Hideki Garren, M.D., Ph.D. resigned from the Board on November 1, 2024. |
| 2024-11 | Dr. Berman has been Executive Chairman since November 2024 |
| 2024-11 | Dr. Swaminathan assumed the role of Chief Executive Officer in November 2024. |
| 2024-12-31 | For the fiscal year ended December 31, 2024 |
| 2025-03-14 | The number of shares of Registrants common stock outstanding as of March 14, 2025 was 16,724,998. |
| 2025-03-18 | The Original Form 10-K), filed with the Securities and Exchange Commission (the SEC) on March 18, 2025 |
| 2025-04-07 | As of April 7, 2025, awards have been granted and remain outstanding with respect to 3,060,030 shares of our common stock. |
| 2025-04-07 | The following table sets forth information regarding the beneficial ownership of our common stock as of April 7, 2025 |
| 2025-04-28 | Date of certifications of CEO and CFO |
Keywords
Form 10-K/A, amendment, directors, executive compensation, corporate governance, financial statements, Coya Therapeutics, Sarbanes-Oxley, certifications
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.